buy

Progenics Pharmaceuticals buy marge

Progenics Pharmaceuticals

Start price

€7.59

/ 50%

Target price

18.07.16

Performance (%)

End price

€4.60

Summary

This prediction ended on with a price of €4.60. Massive losses of were the result for the BUY prediction by marge. marge has 50% into this prediction

Performance without dividends (%)

Name	1w	1m	1y	3y
Progenics Pharmaceuticals
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by marge for this prediction

In the thread Progenics Pharmaceuticals diskutieren

Prediction Buy

Perf. (%)

Target price 9.020

Change

Ends at

Mit vielversprechenden Onkology-Produkten in der Pipeline.

Progenics Pharmaceuticals (NASDAQ:PGNX) jumps 22% premarket on increased volume in response to its announcement that the FDA has granted Breakthrough Therapy status to Azedra for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma (tumor of the adrenal gland) and paraganglioma. Phase 2b-stage Azedra also has Orphan Drug and Fast Track designations.

Azedra (Ultratrace iobenguane I 131) is a highly specific activity form of the radiotherapeutic iobenquane I 131.

BTD status provides for more intensive guidance from the FDA, the involvement of more senior agency personnel and a rolling review of the New Drug Application (NDA). Orphan Drug status provides for a seven-year period of market exclusivity for the indication, if approved

http://seekingalpha.com/article/3254715-revisiting-the-investment-case-on-progenics-pharmaceuticals

marge